Introduction
Burkitt and atypical Burkitt lymphoma are highly aggressive tumors with nearly 100% growth fraction driven by the myc oncogene and highly curative with current therapy. The three major types include endemic African, sporadic and HIV-associated. Though relatively rare in the immunocompetent population, patients with HIV infection are at least 50 times more likely to get lymphoma in general. As 25-40% of these lymphomas will be Burkitt lymphoma [1] [2] [3] , this translates to a 10-20% individual lifetime risk of Burkitt lymphoma for an HIV-infected person. This is largely unaffected by combination antiretroviral therapy (cART), as the risk of Burkitt lymphoma is independent of CD4 cell count.
In the immunocompetent setting, treatment for Burkitt lymphoma has evolved from single agent studies first conducted in endemic African Burkitt lymphoma [4 ] to often complex multiagent regimens [5] [6] [7] [8] [9] [10] none of which have been compared in randomized studies. The addition of high dose cytarabine and methotrexate in doses sufficient to cross the blood-brain barrier and intrathecal prophylaxis led to an improvement in success of Burkitt lymphoma therapy [4 ] and most regimens in use to day incorporate these elements.
Early in the AIDS epidemic, the underlying comorbidities AIDS patients already had at the time of a lymphoma diagnosis precluded intensive chemotherapy. In fact, standard regimens for diffuse large B-cell lymphoma were eschewed because of treatment-related mortality [11] . However, with the advent of combination antiretroviral therapy (cART), patients often presented with a lymphoma in the absence of previous opportunistic infections and even low CD4 cell counts at presentation were often reversible with the institution of cART during or at the completion of chemotherapy. Subsequently, at least three studies published from 2002 to 2004 supported treating AIDS related Burkitt lymphoma aggressively with standard intensive therapies [12] [13] [14] , despite a prevailing view that treatment was futile.
The current manuscript will explore some of the current areas of interest in the treatment of HIV-Burkitt lymphoma. These include optimization of chemotherapy, incorporation of immunotherapy, age appropriate modifications, and biologic uniqueness of HIV-Burkitt lymphoma. As little has been published in manuscript form recently, this review will incorporate recent international conference proceedings.
Chemotherapy backbone
As noted earlier, none of the standard multiagent programs for the treatment of Burkitt lymphoma have been compared in randomized trials. Therefore, adapting a particular regiment to HIV-Burkitt lymphoma is somewhat dependent on a particular institution's predilection for one regimen over another. Two groups with a particular interest in HIV-Burkitt lymphoma have reported interim results in abstract form using very different approaches.
The AIDS Malignancy Consortium (AMC) built upon the Magrath National Cancer Institute regimen CODOX-M/IVAC (Table 1) [8] and modifications made by Lacasce (Table 2) [15] to improve tolerability in adults. Originally, Magrath was successful in a population of HIV-negative children and young adults, but was associated with a nearly universal rate of pancytopenic complications in adults and severe mucositis. The Lacasce modifications included decreasing the dose of methotrexate, whereas maintaining central nervous system penetration, and capping vincristine; and consolidating some of the intrathecal therapies. AMC 048 (Table 3) [16] kept these changes and added some new ones with the intent to reduce further morbidity and mortality. For example, methotrexate was no longer given during the nadir from the first few days of therapy. In the hopes of improved efficacy, rituximab, the anti-CD20 antibody, was added and ifosfamide and etoposide were given as a 5-day infusion rather than bolus therapy.
A planned interim analysis to exclude excess treatment related mortality (TRM) was reported at the 2009 American Society of Hematology (ASH) meeting. With 22 of 31 planned patients accrued as of June 2009, baseline characteristics included: classical Burkitt, 95%; low/high risk, 9/91%; median (range) age 40 (19-55); CD4 cell count 290 (0-1260), CD4 cell count less than 100, 5 (27%); HIV viral load 15 600 (48-715 881). Thus far, the trial had no TRM, only four patients withdrew owing to adverse events and one did not complete the protocol. The latter patient remained in remission, but had less than 1 year of followup. Grade 3/4 toxicities were markedly reduced. With a median follow up of 17 months, the 1-year overall survival (OS) (95% CI) was 85.7% (60%, 100%). Notably, despite concerns raised in a prior AMC study (010) of rituximab and cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) in DLBCL, rituximab did not appear to increase toxicity. These results compared favorably with two studies that excluded HIV positive patients. Magrath [8] originally reported 100% grade 4 hematologic and 20% mucositis in 39 adults, 33 children (92% 2 year EFS) with CODOX-M/IVAC. The Medical Research Council/National Cancer Research Institute Lymphoma 10 (MRC/NCRI LY10) trial [17] used the same regimen with reduced methotrexate (3 g/m 2 ), but reported 9% treatment related deaths (64% 2 year OS). With ongoing enrollment of AMC 048 completed during the second quarter of 2010, it is possible the primary objective of 1 year OS of 85% may be achieved. 
Rituximab
Rituximab, an anti-CD20 antibody, has become a ubiquitous part of regimens directed against B-cell lymphomas, which are largely universally positive for the target cell surface molecule. In randomized studies this antibody when added to a chemotherapy backbone has variously increased response rates, progression free survival and overall survival in a wide variety of indolent and aggressive lymphomas, exclusive of Burkitt lymphoma. This immunotherapy is not specific to the malignant cell and results in temporary ablation of the normal mature B-cell compartment. This raised the concern that patients with already compromised immune systems secondary to HIV might be vulnerable to further immuosuppression. AMC 010, which randomized patients to CHOP with or without rituximab, reported an excess number of deaths in those with CD4 cell counts less than 50 cell/ml [20] . Subsequently, however, both AMC 034 [21 ] and the United States NIH [22 ] reported excellent results with EPOCH-R. Nonetheless, AMC 034 randomized patients receiving concurrent or sequentially rituximab and patients with a baseline CD4 cell count less than 50/ml had a high infectious death rate in the 446 Cancer in AIDS concurrent arm. Thus, for many investigators the true balance of risk and benefit in this highly select group of patients remains unclear. Notably, a retrospective analysis of immunocompetent Burkitt lymphoma patients treated with CODOX-M/IVAC with (n ¼ 47) and without rituximab (n ¼ 40) simply based on the year of presentation, showed only a trend towards improvement in response rate and survival suggesting that increased patient numbers may be needed to demonstrate significance [23] . With the rarity of Burkitt lymphoma, it is unlikely this will be resolved in future trials.
The impact of age on therapy and outcome
The initial studies in Burkitt lymphoma were predominantly on children and younger adults. This was in part owing to the incidence of the disease and the fear that older patients would not tolerate such intensive therapies. However, with an aging population, both immunocompetent and HIV infected, the question of age appropriate therapy for Burkitt lymphoma becomes salient. In fact, a recent epidemiologic study suggests Burkitt lymphoma may have a geriatric peak [24, 25 ] . Moreover, the HIV population is aging with fewer years of life lost attributable to HIV [25 ] and some projections of normal life expectancy in a significant proportion of treated individuals [26 ] . A recent attempt to review the treatment of Burkitt lymphoma in individuals over 40 primarily highlighted the paucity of available data [27 ] . The impact of aging vis a vis HIV and Burkitt lymphoma remains to be elucidated.
Does HIV status matter?
Implicit in these discussions is that treatment of HIV-Burkitt lymphoma can be imported from studies in the immunocompetent patient population. However, this may not be entirely true. First, one notes the issues raised earlier of toxicity with anti-CD20 therapy in the most immunocompromised. Perhaps more importantly, the pathobiology of HIV lymphomas is not necessarily identical to those presenting in the absence of HIV despite their shared similarities under the microscope. Several observations suggest this to be true. First is the well described predilection of HIV-lymphoma to present with extranodal involvement. in contrast to frequent intact signaling in DLBCL lines derived from immunocompetent individuals [29] . The multidrug resistance P-glycoprotein (Pgp) may also be much higher in HIV-positive lymphomas influencing response to chemotherapy. Epigenetic changes (such as silencing of the O-6 methylguanine methyl transferases) [30] may additionally play a role, although the relationship to HIV infection and immunohistochemical subtypes is incompletely explored. Finally, a recent analysis using single nucleotide polymorphism (SNP)-based microarray comparative genomic hybridization of AIDS and immunocompetent DLBCLs revealed significant differences between subtypes of lymphoma and differences between those with and without host-HIV infection [31 ] . Elucidating these pathways could reveal new targets for therapy with small molecule inhibitors or other strategies. These could prove to augment current strategies or replace them with less toxic options.
Studies in Africa
It is worth mentioning that Burkitt lymphoma was originally discovered in Africa by Dennis Burkitt and many of the original single agent trials were conducted there; the benefits of multiagent therapy have only rarely been applicable to endemic Burkitt lymphoma. It remains to be seen whether the increasing availability of cART in Africa will facilitate the treatment of Burkitt lymphoma [32] . It is also possible that improved life expectancy from an HIV perspective will result in a surge in the incidence of Burkitt lymphoma.
Conclusion
Burkitt lymphoma is a rare disease in the immunocompetent population, but is disproportionally common in the HIV-infected population. Epidemiology suggests the incidence may further increase with the aging population. Early studies in the cART era refute the nihilistic approach to this disease prior to cART. More recently trials are largely borrowing from those conducted in the immunocompetent population, although changes are being tested to reduce the morbidity of treatment for all patients. Whether high dose methotrexate and cytarabine can be eliminated, facilitating outpatient therapy remains an open question. The impact of rituximab also remains undefined. Finally, the pathobiologic influence of HIV and the opportunity for future targeted therapy remains largely unexplored.
